Victoza® (liraglutide) injections are a GLP-1 receptor agonist, a drug class experiencing shortages due to their high demand.
Victoza® (liraglutide) injections are a GLP-1 receptor agonist, a drug class experiencing shortages due to their high demand.
While no clear link is established to these obesity and diabetes drugs, the FDA will continue to monitor data.
Exuua was approved for major depressive disorder, while two diabetes medications receive generic approvals.
Tzield (teplizumab-mzwv) injections can delay onset by several months or years.
